Initial Systemic Therapy Options
Part 1: Introduction
Part 2: Targeting the VEGF Pathway in Metastatic RCC
Part 3: mTOR Inhibition in Renal Carcinoma
Part 4: Observation / Clinical Trial as Initial Systemic Therapy in Metastatic RCC
Part 5: Initial Systemic Therapy
Release Date: January 21, 2009
Expiration Date: January 21, 2010
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Estimated Time of Completion: 1 hour
Description
The biology of kidney cancer has been elucidated recently, identifying the vascular endothelial growth factor (VEGF) in mammalian target of rapamicin (mTOR) as viable biologic targets in the treatment of this disease. The existing data regarding therapeutic approaches against these targets will be covered in this webcast to highlight the clinical benefits that have been achieved. In addition, the limitations of the data including both efficacy and toxicity will be discussed. Last, kidney cancer has a unique and variable biology. This will be discussed in the clinical context of identifying the appropriate timing and type of therapy for each patient.
Objectives
At the conclusion of this activity, the participant will be able to:
- Review existing data regarding VEGF- and mTOR-targeted therapy in RCC with regards to objective response rate, PFS and overall survival.
- Identify limitations of the data regarding efficacy and toxicity of targeted agents in RCC.
- Discuss the variable natural history of RCC and the potential for individualized treatment approaches depending on patient and disease characteristics.
Target Audience
This activity is directed to medical oncologists and urologists.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director(s)
Brian Rini, MD |
Planning Committee
Thomas Hutson, D.O., PharmD. |
Christopher Wood, M.D., FACS |
Moderator
Jeffrey Sosman, MD |
Faculty
Robert Figlin, MD |
Martin Gore, MD |
Gary Hudes, MD |
Brian Rini, MD |
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
| Robert Figlin, MD | |||
| Consulting; Independent Contractor: |
Novartis; Pfizer; Wyeth | ||
| Martin Gore, MD | |||
| Consulting; Teaching & Speaking; Membership on advisory committee or
review panels: |
AstraZeneca; Bayer; Pfizer; Roche | ||
| Gary R. Hudes, MD | |||
| Consulting; Membership on advisory committee or review panels: |
Genentech; Novartis; Pfizer; Wyeth | ||
| Thomas Hutson, MD | |||
| Consulting; Teaching & Speaking; Membership on advisory committee or review panels: |
Bayer; Pfizer; Wyeth | ||
| Independent Contractor: | Bayer; GSK; Pfizer; Wyeth | ||
| Brian Rini, MD | |||
| Consulting; Membership on advisory committee or review panels: | Genentech; Novartis; Pfizer; Wyeth | ||
| Christopher Wood, MD | |||
| Consulting; Teaching & Speaking: | Ethicon; Pfizer | ||
The following faculty has indicated he/she has no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
Jeffrey Sosman, MD
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and UNITECH Communications®.
